Literature DB >> 31026039

Activation of TRPA1 by volatile organic chemicals leading to sensory irritation.

Jeanelle M Martinez1, Thomas E Eling1.   

Abstract

Many volatile organic chemicals (VOCs) have not been tested for sensory pulmonary irritation. Development of in vitro non-animal sensory irritation assay suitable for a large number of chemicals is needed to replace the mouse assay. An adverse outcome pathway (AOP) is designed to provide a clear description of the biochemical and cellular processes leading to toxicological effects or an adverse outcome. The AOP for chemical sensory pulmonary irritation was developed according to the Organization for Economic Co-operation and Development guidance including the Bradford Hill criteria for a weight of evidence to determine the confidence of the AOP. The proposed AOP is based on an in-depth review of the relevant scientific literature to identify the initial molecular event for respiratory irritation. The activation of TRPA1 receptor (transient receptor potential cation channel, subfamily A, member 1) is the molecular initial event (MIE) leading to sensory irritation. A direct measure of TRPA1 activation in vitro should identify chemical sensory irritants and provide an estimate of potency. Fibroblasts expressing TRPA1 are used to determine TRPA1 activation and irritant potency. We report a linear relationship between the in vivo RD₅₀ and the in vitro pEC₅₀ values (R=0.81) to support this hypothesis. We propose that this in vitro assay after additional analysis and validation could serve as a suitable candidate to replace the mouse sensory irritation assay.

Entities:  

Keywords:  sensory pulmonary irritation; TRPA1; neurogenic inflammation; TRPV1; non-animal test

Mesh:

Substances:

Year:  2019        PMID: 31026039      PMCID: PMC6829608          DOI: 10.14573/altex.1811012

Source DB:  PubMed          Journal:  ALTEX        ISSN: 1868-596X            Impact factor:   6.043


  55 in total

Review 1.  A painful trp can be a bonding experience.

Authors:  Zita Peterlin; Alexander Chesler; Stuart Firestein
Journal:  Neuron       Date:  2007-03-01       Impact factor: 17.173

2.  TRPA1: Acrolein meets its target.

Authors:  Satyanarayana Achanta; Sven-Eric Jordt
Journal:  Toxicol Appl Pharmacol       Date:  2017-03-08       Impact factor: 4.219

3.  TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents.

Authors:  Diana M Bautista; Sven-Eric Jordt; Tetsuro Nikai; Pamela R Tsuruda; Andrew J Read; Jeannie Poblete; Ebenezer N Yamoah; Allan I Basbaum; David Julius
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

4.  Cigarette smoke-induced neurogenic inflammation is mediated by alpha,beta-unsaturated aldehydes and the TRPA1 receptor in rodents.

Authors:  Eunice Andrè; Barbara Campi; Serena Materazzi; Marcello Trevisani; Silvia Amadesi; Daniela Massi; Christophe Creminon; Natalya Vaksman; Romina Nassini; Maurizio Civelli; Pier Giovanni Baraldi; Daniel P Poole; Nigel W Bunnett; Pierangelo Geppetti; Riccardo Patacchini
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

5.  Intracellular alkalization causes pain sensation through activation of TRPA1 in mice.

Authors:  Fumitaka Fujita; Kunitoshi Uchida; Tomoko Moriyama; Asako Shima; Koji Shibasaki; Hitoshi Inada; Takaaki Sokabe; Makoto Tominaga
Journal:  J Clin Invest       Date:  2008-11-13       Impact factor: 14.808

6.  Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases.

Authors:  Bret F Bessac; Michael Sivula; Christian A von Hehn; Ana I Caceres; Jasmine Escalera; Sven-Eric Jordt
Journal:  FASEB J       Date:  2008-11-26       Impact factor: 5.191

7.  The involvement of TRP channels in sensory irritation: a mechanistic approach toward a better understanding of the biological effects of local irritants.

Authors:  Ramona Lehmann; Nicole Schöbel; Hanns Hatt; Christoph van Thriel
Journal:  Arch Toxicol       Date:  2016-04-01       Impact factor: 5.153

8.  TRPA1 is a major oxidant sensor in murine airway sensory neurons.

Authors:  Bret F Bessac; Michael Sivula; Christian A von Hehn; Jasmine Escalera; Lauren Cohn; Sven-Eric Jordt
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

9.  Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.

Authors:  Mathieu Vinken; Brigitte Landesmann; Marina Goumenou; Stefanie Vinken; Imran Shah; Hartmut Jaeschke; Catherine Willett; Maurice Whelan; Vera Rogiers
Journal:  Toxicol Sci       Date:  2013-08-14       Impact factor: 4.849

10.  Transient receptor potential A1 channels: insights into cough and airway inflammatory disease.

Authors:  Maria G Belvisi; Eric Dubuis; Mark A Birrell
Journal:  Chest       Date:  2011-10       Impact factor: 9.410

View more
  4 in total

Review 1.  A TRiP Through the Roles of Transient Receptor Potential Cation Channels in Type 2 Upper Airway Inflammation.

Authors:  Wout Backaert; Brecht Steelant; Peter W Hellings; Karel Talavera; Laura Van Gerven
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-18       Impact factor: 4.806

2.  A short-term inhalation study to assess the reversibility of sensory irritation in human volunteers.

Authors:  Stefan Kleinbeck; Michael Schäper; Marlene Pacharra; Marie Louise Lehmann; Klaus Golka; Meinolf Blaszkewicz; Thomas Brüning; Christoph van Thriel
Journal:  Arch Toxicol       Date:  2020-03-17       Impact factor: 5.153

Review 3.  Targeting Chemosensory Ion Channels in Peripheral Swallowing-Related Regions for the Management of Oropharyngeal Dysphagia.

Authors:  Mohammad Zakir Hossain; Hiroshi Ando; Shumpei Unno; Junichi Kitagawa
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

4.  Effect of dibenz(b,f)-1,4-oxazepine aerosol on the breathing pattern and respiratory variables by continuous recording and analysis in unanaesthetised mice.

Authors:  Rajagopalan Vijayaraghavan; Utsab Deb; Pranav Kumar Gutch
Journal:  Toxicol Rep       Date:  2020-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.